EcN expressing acylphosphatidylethanolamines (NAPEs) or GLP-1 analog may have potential as a therapeutic intervention for obesity, leading to the inhibition of weight gain, food intake, adiposity, insulin resistance, and hepatosteatosis reduction and maintaining lower plasma leptin and insulin levels. The gene discussed is LEP; the disease is obesity disorder.